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Peroxisome-proliferator activator receptor γ (PPARγ) is a nuclear receptor of central importance in energy homeostasis and
inflammation. Recent experimental pieces of evidence demonstrate that PPARγ is implicated in the oxidative stress response,
an imbalance between antithetic prooxidation and antioxidation forces that may lead the cell to apoptotic or necrotic death. In
this delicate and intricate game of equilibrium, PPARγ stands out as a central player devoted to the quenching and containment
of the damage and to foster cell survival. However, PPARγ does not act alone: indeed the nuclear receptor is at the point of
interconnection of various pathways, such as the nuclear factor erythroid 2-related factor 2 (NRF2), Wnt/β-catenin, and forkhead
box proteins O (FOXO) pathways. Here we reviewed the role of PPARγ in response to oxidative stress and its interaction with
other signaling pathways implicated in this process, an interaction that emerged as a potential new therapeutic target for several
oxidative-related diseases.
1. Introduction
1.1. On Reactive Oxygen Species and Oxidative Stress. Re-
active oxygen species (ROS) are free radicals and reac-
tive metabolites containing oxygen with unpaired electron;
potentially harmful, they act as potent oxidants for lipids,
proteins, and DNA [1]. Small amount of ROS are nor-
mally produced by mitochondrial respiratory chain during
metabolic reactions [2]; however they are not unnecessary
and unavoidable byproducts of the respiratory chains. In
fact, it is fairly accepted that the cells may produce ROS
intentionally and that ROS play an important role in
cellular processes such as cell-cycle progression, regulation
of signaling pathways in response to intra- and extracellular
stimuli, and inflammation [3–5].
Because high levels of ROS may be detrimental, the
cells possess a vast array of antioxidant systems devoted to
ROS neutralization and maintaining of a balance between
prooxidants and antioxidants. We distinguish two types of
antioxidants: enzymatic and nonenzymatic (or chemical).
Enzymatic antioxidants are proteins such as superoxide
dismutase (SOD), glutathione peroxidase (GPx), glutathione
reductase, and catalase, while chemical antioxidants are
scavenger molecules such as vitamin C and D and glu-
tathione (GSH) [6]. Prooxidants are enzymes like NADPH
oxidase, cyclooxygenase 2 (COX-2), and inducible nitric
oxide synthase (iNOS) [7–9].
When the near equilibrium condition between prooxi-
dants and antioxidants is perturbed, the ensuing imbalance
determines the so-called oxidative stress. During oxidative
stress the sustained production of ROS and of other high
reactive species, not sufficiently quenched by antioxidants,
may deal significant damage to the cells, and, if too much
damage is done, that may lead to necrotic or apoptotic cell
death.
Excessive ROS production and oxidative stress is believed
to be the cause, or is linked to, the establishment of several
pathologies (for a list see [6]), including alcoholic and
nonalcoholic fatty liver disease (NAFLD) [10, 11]. ROS
production and oxidative stress are also associated with the
pathogenesis of HIV, HCV, andHBV viral infections [12–14].
1.2. PPARγ. The Peroxisome-proliferator activator receptors
(PPARs) form a family of ligand-activated nuclear recep-
tor transcription factors that regulates the function and
expression of complex gene networks, especially involved in
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energy homeostasis and inflammation [15–17]. The family
comprises three knownmembers: PPARα, PPARγ, and PPAR
β/δ, also known as NR1C1, NR1C3, and NR1C2 [18].
Among the PPARs, PPARγ is the only receptor known to
possess three splicing isoforms characterized by a different
tissue distribution [15, 16].
PPARγ shares a protein structure common to the other
PPARs and to most of the nuclear receptors characterized
by 4 functional domains (called from the N terminal to the
C terminal, A/B, C, D, and E/F) [15, 19]. The N-terminal
region, corresponding to the A/B domain, contains the AF-
1 domain (implicated in ligand-independent activation);
the highly conserved DNA-binding domain, located in
the C domain, is separated by the flexible hinge domain
of the D region (to whom dock coactivators) from the
moderately conserved ligand-binding domain (E/F domain)
that contains also the AF-2 region for ligand-dependent
activation that is also essential for coactivators recruitment
[15, 16, 19].
PPARγ does not act alone but regulates genes transcrip-
tion acting as heterodimer with the retinoid X receptor
(RXR) [15, 16]. As dimers, PPARγ : RXR bind to PPAR
response elements (PPREs) located in the promoter region
of target genes. PPREs are hexanucleotide direct repeat
consensus elements, whose sequence is AGGTCA, separated
by one or two bases (known as Direct Repeat 1 (DR-1) and 2
(DR-2)).
The activity of PPARγ in a cell context depends on
the presence of other molecules such as coactivators and
corepressors, expression of other PPARs, availability of RXR,
the status of promoter of the target genes, and presence of
endogenous ligands [20]. Activation of PPARγ is canonically
obtained through ligand binding. The ligand-binding deter-
mines a conformational change in the three-dimensional
structure of PPARγ : RXR dimers that is accompanied by
loss of heat shock proteins, detachment of corepressors,
and recruitment of coactivators [15, 16, 21]. Changes in
nuclear localization of PPARγ have also been described
[22]. Akiyama et al. [22] utilizing fluorescent-tagged PPARγ
and RXR demonstrated that PPARγ nuclear distribution
changes after the coexpression of RXR independently from
the presence or absence of PPARγ- or RXR-specific ligands,
suggesting that RXR is implicated in the nuclear reorganiza-
tion of PPARγ.
The activation status of PPARγ may also be mod-
ulated by posttranslational modifications, such as phos-
phorylations, independently from ligand binding [21, 23].
Indeed, the mitogen-activated protein kinase(s) (MAPK)
p38, extracellular-signal-regulated kinase (ERK), and c-
Jun N-terminal kinases (JNKs) are able to phosphorylate
PPARγ [21]; this event is usually associate with inhibition
of transcriptional activity [21], cytoplasmic localization [24,
25], and possibly degradation [26] of PPARγ. The activated
receptor then binds to PPRE: the net results of this complex
mechanism are changes in the expression level of mRNAs
encoding PPARγ target genes.
PPARγ may also influence genes expression with a
mechanism known as transrepression. Transrepression does
not require DNA binding of the activated receptor to the
PPRE and has been invoked to explain anti-inflammatory
action of PPARγ [27–30]; several models to explain the
transrepression have been proposed including competition
for coactivators molecules, for co-receptors, or for the
binding sites [31].
The experimental evidence that oxidized lipids and 15-
deoxy-delta (12, 14)-prostaglandin J(2) (15d-PGJ2), which
are natural endogenous PPARγ ligands [32], are produced
during oxidative stress and inflammation suggests that
PPARγ is implicated in oxidative stress response. This
hypothesis is also corroborated by the sheer number of
scientific papers published on this topic: in fact, a query
for “PPARγ and oxidative stress” in PubMed returns (as to
August 2011) at least 300 publications.
Given that various pathologies are associated to oxidative
stress and PPARγ is emerging as an important regulator
of the response to this condition, in this paper we will
summarize the current understanding of the role of this
nuclear receptor in response to oxidative stress and its
interaction with other signaling pathways implicated in this
process.
2. PPARγ and Oxidative Stress Response
2.1. PPARγ: An Emerging Anti-Inflammatory and Antioxi-
dant Gene. The insulin-sensitizing drugs thiazolidinediones
(TZDs), used in the treatment of type II diabetes, are PPARγ-
specific agonists. Together with other PPARγ agonists, they
are used or are under studies for the treatment of oxidative
stress-related diseases such as diabetes, vascular diseases [33–
35], Parkinson’s [36], Alzheimer’s [37], nonalcoholic steato-
hepatitis (NASH) [38], and Huntington’s [39]. It is worth
noting that although for a long time TZD effects have been
thought to be PPARγ dependent, TZD PPARγ-independent
effects have been widely described and may coexist with
the PPARγ-dependent effects [40–44]. As examples, TZDs
have anticancer activity in the liver, independently of PPARγ,
via inhibition of nucleophosmin that is associated with
the induction of p53 phosphorylation and p21 expression
[40]; in QZG hepatocytes rosiglitazone, independently of
PPARγ, decreases ROS generation induced by high glu-
cose treatment, whereas it induces the antioxidant enzyme
heme-oxygenase 1 (HO-1) in a PPARγ-dependent manner
[41].
Nonetheless, PPARγ may directly modulate the expres-
sion of several antioxidant and prooxidant genes in response
to oxidative stress (Figure 1). The mouse, human, and rat
catalase [45, 46], a major antioxidant enzyme that decom-
poses H2O2 to H2O and O2, is transcriptional regulated by
PPARγ through PPREs containing the canonical DR-1 [46]
and that may be located as far as 12 kb from the transcription
initiation site [45]. Interestingly, H2O2 induces apoptosis in
cardiomyocytes [47] through a marked downregulation of
the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) and
may reduce PPARγ expression in HUVEC cells, an effect
that is reverted by catalase [48]. Besides, PPARγ protects
cardiomyocytes and glial cells from oxidative stress-induced
apoptosis inducing Bcl-2 [47, 49]. This prosurvival action
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Figure 1: PPARγ target genes and cellular roles. In oxidative stress conditions the nuclear receptor PPARγ directly regulates a vast array of
genes involved in the response to oxidative stress and exerts anti-inflammatory effects transrepressing NF-κB.
of PPARγ is probably independent of the MAPKs and AKT
pathways [47, 49].
Furthermore, ligand-activated PPARγ promotes the
expression of manganese SOD (MnSOD) [50, 51], GPx3
[52], the scavenger receptor CD36 [53, 54], endothelial
nitric oxide synthase (eNOS) [33], HO-1 [41, 55, 56], and
the mitochondrial uncoupling protein 2 (UCP2) [35, 38],
whereas it downregulates COX-2 and iNOS [29, 57–59].
The activity of mitochondrial MnSOD, which oversees
the dismutation of O2
− to O2 and H2O2, is increased
by rosiglitazone [50]; moreover in PPARγ knockout mice
MnSOD is downregulated at the transcriptional and trans-
lational levels with a consequent increase of O2
− levels [51].
In fact, promoter analysis revealed that MnSOD is a direct
target of PPARγ [51].
GPx protect cells from oxidative stress in two ways,
reducing H2O2 to H2O and O2 (like the previously cited
catalase) and acting as scavenging for oxidized lipids.
Recently, Chung et al. [52] demonstrated that in human
skeletal muscle cells TZD-mediated activation of PPARγ
induces GPx3 and protects from oxidative stress.
In spontaneous hypertensive rats, oral intake of rosiglita-
zone upregulates UCP2 and the protective effects of rosiglita-
zone are abrogated silencing PPARγ [35]. The mitochondrial
UCP2 may protect from oxidative stress preventing the
accumulation of O2
− in the mitochondria and facilitating
the transport of mitochondrial ROS to the cytosol, where
they would stimulate the expression of neuroprotective genes
(e.g., MnSOD and Bcl-2) [60].
The expression of the scavenger receptor CD36 that
mediates the recognition and internalization of oxidized
lipids [61] may also be regulated by PPARγ. In fact, it
has been demonstrated that in murine macrophages CD36
expression increases after the treatment with PPARγ ligands
[54], probably as a consequence of PPARγ binding to
functional active PPRE located in the gene promoter [53].
PPARγ modulates the expression of eNOS and iNOS [29,
33, 59]. These enzymes produceNO from arginine; whenNO
is produced in high quantities it may react with O2
− forming
the highly reactive peroxynitrite. In mice with an endothelial
specific knockout of PPARγ aortic segments release less
nitric oxide than those from controls and the reduced
expression correlates with an increase in the parameters of
oxidative stress [33], suggesting that PPARγ protect from
oxidative stress controlling eNOS expression. Conversely, the
high production of NO by iNOS is usually associated to
complex immunomodulatory and antitumoral mechanisms
and dysfunctional induction of iNOS expression seems to be
involved in the pathophysiology of several human diseases
[9]. PPARγ agonists repress iNOS expression in various cells
such as activated macrophages [59], lipotoxic pancreatic
islets [29], and lipopolysaccharide-(LPS-) activated Schwann
cells [62] suggesting a protective role of PPARγ from reactive
peroxynitrite.
COX-2 is an inducible form of ciclooxygenase that
contributes to the metabolism of arachidonic acid forming
prostaglandin H2 (PGH2), a precursor of 15d-PGJ2 [7, 8].
The production of PGH2 requires the presence of free
radicals andmay also produce O2
−, contributing to oxidative
stress. Besides, PGH2 also inhibits apoptosis, favors cell
adhesion, motility, invasion, and promotes angiogenesis [8].
How PPARγ acts on COX-2 expression is still debated. In
fact during oxidative stress a PPARγ-mediated inhibition as
well as induction of COX-2 has been reported [41, 57, 58].
Collino et al. [58] and Zhao et al. [57] reported that the
PPARγ agonist pioglitazone and rosiglitazone protect the
cells from oxidative stress after ischemia suppressing COX-2
expression in a PPARγ-dependent manner [57]; conversely,
Wang et al. [41] demonstrated that high glucose significantly
reduced the expression of COX-2 and rosiglitazone upregu-
lated COX-2 expression in a PPARγ-dependent manner. This
latter result is in agreement with that of Aleshin et al. [63]
that described a TZDs enhancement of LPS-induced COX-2
expression via PPARγ-dependent pathway.
Still debated is also the effect of PPARγ on the expres-
sion of HO-1. HO-1 can be strongly induced in many
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tissues in response to cellular stress caused by a wide
spectrum of stimuli, including ROS and prostaglandins
[64]. Enzymatic activity of HO-1 reduces oxidative stress,
diminishes inflammatory response, and lowers the rate of
apoptosis [64]. In human vascular cells PPARγ induces HO-1
expression interacting with two PPRE DR-1 located between
−1740 kb and−1826 kb from the transcription start site [55].
Moreover PPARγ increases the expression of HO-1 during
oxidative stress induced by high glucose [41] and in the age-
related macular degeneration [56]; however rosiglitazone
decreases the expression of HO-1 in the hippocampus after
the status epilepticus [50]. To further complicate the subject,
PPARγ agonist 15d-PGJ2 may induce HO-1 independently
of PPARγ via nuclear factor erythroid 2-related factor 2
(NRF2) [65] or GSH-dependent mechanisms [42].
PPARγ may also influence the antioxidant and anti-
inflammatory responses interacting with other regulatory
pathways. PPARγ has shown to induce anti-inflammatory
responses inhibiting proinflammatory transcription factors
such as nuclear factor Kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) [28–30, 66] (Figure 1). The NF-κB
factors are of central importance in inflammation and their
role in response to ROS has been recently reviewed [7].
NF-κB action is usually proinflammatory and prooxidant
inducing the expression of genes such as iNOS and COX-
2, but it may also regulate the expression of SOD and
other anti-inflammatory genes [7]. PPARγ may reduce NF-
κB activities in various ways. PPARγ transrepresses NF-κB
activation either by forming a repressor complex in the
promoter of NF-κB-target genes or by direct binding with
NF-κB [28–30]; moreover the nuclear receptor may reduce
NF-κB activation mediated by H2O2 [66] probably through
increased expression of catalase [45, 46]. Conversely, NF-
κB negatively regulates PPARγ transcriptional activity with a
mechanism that requires the presence of histone deacetylase
3 (HDAC3) [67, 68]. Interestingly, NF-κB could, potentially,
also induce PPARγ via a thioredoxin- (TRX-) dependent
mechanism. TRX is a potent antioxidant protein whose
expression depends on NF-κB [7]; the activity of TRX is
negatively modulated by the TRX-binding protein-2 (TBP-
2) [69]. TBP-2 null mice treated with a methionine-choline-
deficient diet show simple steatosis but not steatohepatitis
with reduced oxidative stress and increased expression of
PPARγ, suggesting a link between TRX-TBP-2 and the
nuclear receptor [69].
Furthermore, new experimental pieces of evidence sug-
gest that PPARγ modulates oxidative stress responses inter-
acting with NRF2 and the Wnt/β-catenin and forkhead box
proteins O (FOXO) pathways.
2.2. Interacting with NRF2. The nuclear factor erythroid 2-
related factor 2 (NRF2), a redox-sensitive member of the
cap “n” collar basic leucine zipper family, plays a vital role
in cytoprotection against oxidative and electrophilic stress as
well as in suppression of inflammation [70].
Expression of NRF2 is tightly regulated by the Kelch-
like ECH-associated protein 1 (Keap1) [71], an E3 ubiquitin
ligase, that mediates also the downregulation of NF-κB
signaling by targeting the inhibitor of NF-κB subunit β
(IKKβ) [72].
In unstressed conditions, NRF2 remains in the cytosol
and it is rapidly degraded by proteasome after Keap1-
mediated ubiquitination. In presence of ROS or electrophilic
agents, the degradation ceases and NRF2 translocates and
accumulates in the nucleus where it regulates the transcrip-
tion of genes containing in the promoter region the antiox-
idant response element (ARE). NRF2 nuclear translocation
and transcriptional activity depend also on the phosphory-
lation status of the transcription factor [41, 73–75]; AKT-,
p38-, and protein-kinase-C-(PKC-) induced phosphoryla-
tion seems to be the principal mechanism in NRF2 activation
[41, 73–75].
The number of targets of NRF2 is continuously expand-
ing and comprises NADPH-generating enzymes [76], glu-
tathione S-transferase (GST) [77], CD36 [54, 74], HO-1
[65, 75], and NRF2 itself [78].
Recently, microarray analysis of NRF2 target genes
demonstrated that PPARγ expression is compromised in
NRF2 null mice, in normal and stress conditions [79–81]. In
the lungs of NRF2 null mice, hyperoxia-induced expression
of PPARγ was markedly reduced compared to wild-type
animals [79, 80], whereas in the liver of 6-month old NRF2
null mice the genes involved in lipid synthesis and uptake,
including PPARγ, were generally downregulated compared
with the wild-type mice [81]. The PPARγ reduced expression
is a direct effect of the lack of NRF2; in fact both Huang et al.
[81] and Cho et al. [80] demonstrated that NRF2 induces
PPARγ expression binding to at least two ARE sequences
(−916 and −784 ARE, resp.) in the upstream promoter
region of the nuclear receptor.
As previously stated, PPARγ agonists exert potent anti-
inflammatory activities; interestingly, rosiglitazone and other
PPARγ ligands such as 15d-PGJ2 increase NRF2 expression
dependently from PPARγ [73, 77, 82]. Furthermore, NRF2
expression is attenuated in the lung of mice with decreased
PPARγ levels and putative PPREs have been identified on
NRF2 gene promoter [77, 80]; this suggests that a positive
feedback loop exists among PPARγ and NRF2, where PPARγ
may act directly or through upstream pathways for NRF2
activation. This circuit may not only explain the effects of
PPARγ agonists on NRF2 expression but may also contribute
to the anti-inflammatory effects associated with PPARγ
activation. Thimmulappa et al. [83] demonstrated that NRF2
deficiency causes greater sensitivity to septic shock and
results in disregulation of the expression of effector genes of
the innate immunity that are under the control of NF-κB,
increasing lung inflammation. In fact, NRF2 regulates NF-κB
activation largely by modulating its MyD88-dependent and
-independent upstream signaling components; the restrain
of proinflammatory signaling pathways is apparently associ-
ated with the NRF2 ability to maintain redox homeostasis.
In this sense, the PPARγ-mediated activation of NRF2 sig-
naling, which results in NRF2-dependent inhibition of
proinflammatory pathways, may strengthen, and contribute
to, the anti-inflammatory activity of PPARγ.
The altered expression of genes involved in inflammation
and lipid metabolism in NRF2 null mice is interesting for
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the pathogenesis of NAFLD and its progression to NASH.
Lack of NRF2 in mice exposed to high-fat or methionine-
choline diet increases the oxidative stress-related damage
and the lipid accumulation mediated by LXRα [84, 85]. The
pathogenesis of humanNASH is usually explained by a “two-
hit” model where the “first hit” is the steatosis and the second
is constituted by many factors, including oxidative stress.
Although there is a controversy on the relationship between
high-fat diet feeding and NRF2 expression in mice (both
increase and decrease of gene expression have been reported
[85]), human samples from steatotic livers show a marked
decrease inNRF2 expression [85]. Reduced expression or loss
of NRF2 and/or PPARγmay increase oxidative stress that acts
as “second hit” in NASH; in fact, on the basis of experimental
evidence, we may hypothesize that NRF2, together with
PPARγ, preserves from the progression of NASH throughout
protective effects on oxidative stress, inflammation, and lipid
metabolism.
What is certain is that PPARγ is not a simple downstream
effector of the NRF2 pathway but may also act synergically
with NRF2 in the activation of antioxidant genes [54, 77].
In the GSTA2 promoter ARE and PPRE response elements
coexist [77]; Park et al. [77] demonstrated that the ARE site
had essential roles in the transactivation of the GSTA2 gene
by PPARγ and RXR ligands, as evidenced by the binding
site-deleted promoter-luciferase assay, and it is necessary for
the full gene transactivation [77]. Similarly the expression
of the scavenger receptor CD36 in murine macrophages is
dependent on both proteins [53, 54]. On the other hand, the
case of the CD36 is also explanatory of the fact that PPARγ
and NRF2may act independently to induce the transcription
of the same gene, depending on the cellular context. In
murine macrophage, oxidized lipids that in macrophages
induce a PPARγ-dependent CD36 expression [53, 54], in
preadipocytes induce a mostly PPARγ-independent expres-
sion of the scavenger [74]; the latter is associated to increase
expression and nuclear translocation of NRF2 consequently
to PKC activation [74].
2.3. The Involvement of Wnt/β-Catenin Pathway and FOXO
and Their Interaction with PPARγ. The Wnt/β-catenin path-
way is a well-known morphogenic signaling pathway first
discovered in colon carcinoma [86]. From this very first
discovery the role of Wnt and β-catenin has been described
in several processes including morphogenesis, maintenance
of stem cells characteristics but also cell differentiation, cell
survival, and lipid and glucose metabolism [87–91]; in fact
Wnt pathway belongs to a restricted group of extremely
evolutionary conserved signaling cascades. The pathway is
complex and quite versatile in terms of end effects on cellular
behavior.
The main effector of Wnt, in the canonical pathway, is
the bipartite transcription β-catenin-DNA binding protein
T cell factor/lymphoid enhancer factor (TCF/LEF) [86];
Wnt may also act independently of β-catenin in the so-
called noncanonical pathway [92, 93] and regulate proteins
translation via mTOR [94].
β-catenin is constitutively expressed in the cytoplasm,
but its activity is regulated at the posttranscriptional level
through phosphorylation. β-catenin phosphorilation is per-
formed by a degradation complex comprised, among other
proteins, of glycogen synthase kinase 3 beta (GSK3β) and
adenomatous polyposis coli (APC) and results in ubiquiti-
nation and degradation by the proteasome.
Conversely, the binding of Wnt glycoproteins to the
seven pass membrane receptor Frizzled and coreceptors low-
density lipoprotein receptor-related protein 5/6 (LRP5/6)
results in GSK3β phosphorylation followed by the stabi-
lization and nuclear translocation of β-catenin, and hence
activation of the pathway. To add further complexity to the
system, other signaling pathways, such as the insulin and
insulin-like growth factor 1 (IGF-1) pathways, activate β-
catenin possibly through an AKT-dependent GSK3β phos-
phorylation [95, 96].
Recent experimental pieces of evidence suggest that the
Wnt/β-catenin is deeply involved in the response to oxidative
stress. Products of lipid oxidation activate the canonical Wnt
pathway in a rat model of diabetic retinopathy [97] and Wnt
is implicated in the genesis of diabetes followed by ROS stress
[91]; conversely, ethanol may reduce cellular localization of
β-catenin and TCF/LEF gene transcription in the bone [98],
while nucleoredoxin, a thioredoxin-related protein, that is
inactivated by oxidative stress, blocks the pathway [99, 100].
The Raf kinase inhibitory protein (RKIP), an inhibitor of
the c-Raf and NF-κB, may influence GSK3β phosphory-
lation: RKIP depletion increases ROS-induced p38 MAPK
activation which inhibits GSK3β increasing β-catenin levels
[101]. Furthermore, ROS generation induced by high glucose
destabilizes the β-catenin and induces cell-cycle arrest and
apoptosis [102]. In the mouse, loss of β-catenin in the devel-
oping liver determines embryonic lethality at E17 associated
with increased apoptosis and oxidative stress [103]; these
results are confirmed in mouse diethylnitrosamine-(DEN-)
induced liver carcinogenesis, where the absence of β-catenin
increases the oxidative stress [104]. Interestingly, Wnt/β-
catenin may also be involved in the regulation of antioxidant
enzymes such as GST [105] and cytochrome P450 (CYP)
[106].
The described experimental results not only demonstrate
the involvement of the Wnt/β-catenin in the response to
oxidative stress but also imply that its role is multifaceted.
Interestingly, some of the variegated effects of the Wnt/β-
catenin may be explained by the introduction of another
player in this complex regulatory pathway: the FOXO pro-
teins.
The FOXO subfamily of forkhead transcription factors
is emerging as a fundamental regulator of β-catenin/TCF
activation and plays an important role in stress response
to ROS. In mammals, the FOXO family comprises four
isoforms (FOXO1, FOXO3, FOXO4, and FOXO6) charac-
terized by an overlapping expression during development
and in adulthood. FOXO acts as transcriptional activators
governing a variety of different cellular processes in response
to different environmental contexts specifically promoting
cell-cycle arrest, apoptosis, glucose metabolism, and stress
resistance [107–109]. Kops et al. [107] and Essers et al.
[109, 110] demonstrated that FOXO1, 3, and 4 are also
directly involved in cell responses to ROS inducing the
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MnSOD; FOXO may also regulate catalase production and
reduce β-catenin expression [110]. FOXO activation by ROS
is probably mediated by the JNK MAPK pathway: in fact,
oxidative stress induced by treatment of cells with H2O2
results in the activation of the small GTPase Ral that deter-
mines the phosphorylation and activation of JNK and JNK-
mediated phosphorylation of FOXO1 [109]. Conversely, the
phosphorylation of FOXO proteins mediated by the PI3K-
AKT, p38, or IKKβ kinases inhibits FOXO function inducing
cytoplasmic translocation and protein degradation [108,
111–114].
β-catenin binds directly to FOXO through an evolution-
ary conserved mechanism and enhances FOXO transcrip-
tional activity in mammalian cells [110]. In stress conditions
FOXO proteins compete with TCF for a limited pool of
available β-catenin, thereby inhibiting TCF transcriptional
activity [115, 116]. β-catenin then appears to fulfill a critical
function in balancing TCF signaling (mainly proliferative)
and FOXO signaling (mainly devoted to stress response and
apoptosis).
A cross-talk among PPARγ, β-catenin, and FOXO is
demonstrated by several studies. The existence of an influ-
ence of Wnt/β-catenin on PPARγ expression has been
reported in 2000 when Ross et al. [117] described that Wnt
signaling prevented the adipogenesis by silencing PPARγ
expression; however, the interaction between PPARγ and
Wnt stretches out the adipogenesis and has been described in
several processes where ROS production and oxidative stress
are important such as aging, Alzheimer’s and Parkinson’s dis-
eases, diabetes, hepatic stellate cells activation, liver fibrosis,
and cancer [6, 118–121].
The molecular pathway linking Wnt to the repression of
PPARγ has been elucidated only years after the paper of Ross
et al. [117]; combining gene expression array, chromatin-
immunoprecipitation, and cell-based approach, Okamura
et al. [90] demonstrated that Wnt/β-catenin induces the
orphan nuclear receptor COUP-TFII [133] that recruits
the silencing mediator of retinoid and thyroid hormone
receptors (SMRT) co-repressor complex to the first intron
of PPARγ repressing its transcription [90]. Other regulatory
proteins and networks, such as the Nemo-like kinase NLK
[134], Smad/TFGβ [135], the Wnt co-receptor antagonist
Dickkopf-1 [119, 120], and TNF-α [136, 137], may also
regulate PPARγ interacting with Wnt.
PPARγ agonists such as TZD, GW1929, or 15d-PGJ2
inhibit β-catenin signaling in vitro and in vivo [122–
126]. In human myeloid and lymphoid leukemic cell lines
PPARγ activation induces cell-cycle arrest and apoptosis
downregulating c-Myc through blockade of TCF activity
[126]. In the colon PPARγ activation suppresses epithelial
cell turnover and β-catenin transcriptional activity retaining
the β-catenin in the cytosol [123]. Conversely, the PPARγ
antagonist T0070907 promotes tumorigenesis in the small
intestine and colon stimulating epithelial proliferation: this
effect depends on increased expression of c-myc and Cyclin
D1 genes and β-catenin activation [127, 138].
Several studies have demonstrated that PPARγ directly
interacts with β-catenin [128, 138, 139]. The functional
interaction between β-catenin and PPARγ requires the
presence of PPARγ co-receptor RXR [139] and involves
the TCF/LEF binding domain of β-catenin and a catenin
binding domain within PPARγ [128]. It has been reported
that the ligand-activated PPARγ may retain β-catenin in
the cytosol so reducing its transcriptional activity [138] and
may determine a proteasomal degradation of the protein
[125, 128]; however Lu and Carson [122] did not observe
a reduction in β-catenin expression after TZD treatment in
vitro.
Furthermore, PPARγ may indirectly increase β-catenin
degradation influencing the phosphorylation status of
GSK3β. PPARγ is a known activator of the phosphatase
and tensin homologue deleted on chromosome 10 (PTEN),
a phosphatase that inhibits AKT signaling [140]. Conse-
quently, PPARγ PTEN-mediated antagonism of AKT may
reduce the inhibition of GSK3β enhancing proteasomal
degradation of β-catenin, in agreement with other reports
that have implicated PTEN as a negative regulator of β-
catenin by way of AKT/GSK3β [141].
An axis PPARγ-β-catenin-FOXO has been suggested by
Almeida et al. during oxidative stress in the skeleton [118].
The authors first demonstrated that lipid oxidation, that
causes oxidative stress, and PPARγ expression increase with
aging; the authors then go on demonstrating that ROS acti-
vate FOXO that decrease Wnt/β-catenin by competition; in
turn, the ensuing PPARγ increased expression and activation
further sink β-catenin signaling [118]. However Almeida et
al. [118] did not specify the PPARγ-FOXO relationship.
FOXO may modulate PPARγ at the mRNA and protein
levels [129–131]. In fact, FOXO1 acts as a transcriptional
repressor binding to the PPARγ promoter [130, 131] and
may reduce PPARγ activity through a transrepression mech-
anism that involves a direct protein-protein interaction
[129, 131]. The transrepression mechanism is dependent
on PPARγ activation by its ligands and is mediated by a
31-amino-acid domain within FOXO1 that contains one
inverted and two atypical LXXLL motifs [131]. Likewise it
has been reported that in 293T cells cotransfection with
increasing amounts of expression vectors encoding PPARγ
and RXR results in a dose-dependent inhibition of FOXO1-
driven reporter activation [129], creating a regulatory feed-
back loop PPARγ-FOXO; however it is not clear if the re-
ported effect is due to a transrepression mechanism or is an
indirect effect of PPARγ : RXR dimers.
It has been suggested that PPARγ may regulate FOXO1
through modulation of AKT with a mechanism that may
explain the signal cascade of insulin [131]; this regulatory
circuit could however also act during oxidative stress. As
mentioned before, FOXO proteins are negatively regulated by
PI3k-AKT-mediated phosphorylation; consequently, PPARγ,
inducing PTEN, may block AKT activation and hence may,
indirectly, increase FOXO activity. Interestingly, Sakamoto
et al. [142] demonstrated in PTEN-deficient Jurkat cells an
AKT- and NRF2-dependent enhanced activation of ARE
containing genes; this finding suggests that the regulatory
network PPARγ-PTEN-AKT that acts on FOXO with acti-
vating effects may also act on NRF2; however given that
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Figure 2: Crosstalk of PPARγ with NRF2, Wnt/β-catenin, and FOXO signaling pathways in oxidative stress response. ROS and other
reactive species activate NRF2 and PPARγ that are linked by a positive feedback loop that sustains their expression. Through a negative
feedback PPARγ inhibits Wnt/β-catenin and induces cell block. Activation of FOXO in turn blocks Wnt/β-catenin (diverting β-catenin from
proliferation to resistance and apoptosis) and PPARγ. Finally, the result of these interactions, survival or cell death, depends on the action of
other signaling pathways and regulatory circuits.
AKT increases NRF2 activity [75], the axis PPARγ-PTEN-
AKT, conversely to the effect on FOXO, should reduce NRF2-
induced transcription.
Moreover, PPARγ may influence FOXO acting on p38-
MAPK, SIRT histone deacetylase, and the NF-κB. NF-κB
and p38 inactivate FOXO and increase their ubiquitination-
mediated degradation [111, 113, 114]. PPARγ may coun-
teract the effects of both these pathways: in fact PPARγ
transrepresses (and it is repressed by) NF-κB and influences
the p38 MAPK signaling cascade increasing the expression
of heat shock protein 27 (Hsp27) [143]. The Hsp27, in
turn, possesses antioxidant properties [144] and might act
indirectly on FOXO with both positive and negative effects
(inhibiting NF-κB [145] and activating AKT [146], resp.).
This latter effect may also explain the previously discussed
finding of a PPARγ-dependent inhibition of FOXO1 [129].
Acetylation/deacetylation regulates different functions
of FOXO proteins. It has been demonstrated that the
deacetylase SIRT1 deacetylates FOXO proteins in response
to stress [147, 148], increases the ability of FOXO to induce
cell-cycle arrest, but diverts FOXO-dependent response from
apoptosis [147]; interestingly in the heart, whereas moderate
levels of SIRT protect from oxidative stress, high levels of the
deacetylase may increase the oxidative stress and apoptosis
[148]. SIRT2, that shares similar function with SIRT1,
suppresses adipogenesis by deacetylating FOXO1 to promote
FOXO1’s binding to PPARγ and subsequent repression on
PPARγ transcriptional activity [132]. Furthermore, SIRT1
represses PPARγ by docking with its cofactors nuclear
receptor co-repressor (NCoR) and SMRT [149]. Finally, a
negative feedback and self-regulating loop links SIRT1 to
PPARγ: Han et al. [150] demonstrated that both PPARγ and
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Table 1: Experimental data for PPARγ-modulated genes during oxidative stress.
Target Effect Tissue or cell type
Type of
evidence
References
Bcl-2 ↑ expression Cardiomyocyte and glial cells In vitro [47, 49]
Catalase ↑ expression Adipocytes, microvascular endothelial cells In vitro [45, 46]
CD36 ↑ expression Macrophages In vitro [53, 54]
COX-2 ↑↓ expression Hepatocytes, neurons, pancreatic islets, macrophages, astrocytes In vitro
In vivo
[29, 41, 57–
59, 63]
eNOS ↑ expression Endothelial cell In vivo [33]
GPx3 ↑ expression Skeletal muscle cells In vitro [52]
HO-1 ↑↓ expression Hepatocytes, human vascular cells, retina, hippocampal neurons, In vitro
In vivo
[41, 50, 55, 56]
iNOS ↓ expression Neurons, macrophages, pancreatic islets, Schwann cells In vivo
In vitro
[29, 57–59, 62]
MnSOD
↑ expression
↑ activity Hippocampal neurons, heart In vivo [50, 51]
UCP2 ↑ expression Sympathetic premotor neurons, liver In vivo [35, 38]
↑ = increasing; ↓ = decreasing; ↑↓= increasing and decreasing effects described.
SIRT1 bind the SIRT1 promoter inhibiting the transcription
of the deacetylase; moreover, PPARγ directly interacts with
SIRT1 and inhibits SIRT1 activity; the association SIRT1-
PPARγ appears to be mediated by the acetylation status
of PPARγ [150]. Acetylation of nuclear receptor is usually
associated with an increase in the transcriptional activity;
although there is still no a direct evidence on PPARγ, it has
been demonstrated that during senescence both acetylation
and activity of PPARγ increase [150, 151] suggesting that also
in the case of PPARγ acetylation might increase the activ-
ity. Interestingly, the increased acetylation of PPARγ may
determine an inhibition of SIRT1 via direct binding, thus
limiting the activating deacetylation of FOXO. Furthermore
the inhibition of SIRT PPARγ-mediated may also explain
the finding that PPARγ is involved in the senescence [152].
Paradoxically, inhibition of SIRT1 may increase the risk of
cell death directing the FOXO-dependent response toward
apoptosis [147].
3. Conclusions
A prolonged condition of oxidative stress, as a result of
imbalance between antithetic prooxidation and anti-oxi-
dation forces, may lead the cell to her apoptotic or necrotic
doom.
In this delicate and intricate game of equilibrium, when
the cell may survive or die depending on her ability to sustain
and repair the damage, PPARγ stands out as a central player.
Given that natural ligands of PPARγ are produced
during oxidative stress, PPARγ, if already expressed, may
be one of the first responders directly inducing an arsenal
of antioxidant molecules, inhibiting prooxidants and in the
same time protecting the cells from apoptosis.
It is obvious that in this defense mechanism PPARγ does
not act alone. Indeed the nuclear receptor is at the point of
interconnection of various pathways, specifically the NRF2
and the Wnt/β-catenin and FOXO pathways (Figure 2).
The redox-sensitive nuclear factor NRF2 plays vital role
in cytoprotection against oxidative and electrophilic stress
and is induced by oxidative stress. The pieces of evidence
recollected in this paper demonstrate that PPARγ and NRF2
are linked by a positive feedback loop that sustains the
expression of both transcription factors and of antioxidant
and prosurvival genes, as long as oxidative stress goes on.
At the same time, the two genes exert a potent anti-
inflammatory action inhibiting the NF-κB pathway.
Conversely, PPARγ and the proproliferative Wnt/β-
catenin pathway are associated by a negative feedback loop.
The role of Wnt/β-catenin in response to oxidative stress
is not straightforward: it has been demonstrated that the
pathway is able to positively regulate the expression of some
antioxidant genes and the absence of β-catenin increases
the oxidative stress; however, in light of the interaction
of Wnt/β-catenin with PPARγ, the inhibition of Wnt/β-
catenin pathway may be a necessary step to block cell
proliferation and tomount an antioxidant response inducing
the expression of the anti-inflammatory and antioxidant
PPARγ. Furthermore the block of Wnt/β-catenin pathway
and the diversion of β-catenin from the cognate TCF towards
the FOXO transcription factors increase not only oxidative
stress response but also the rate of apoptosis.
PPARγ interacts also with FOXO. The two transcrip-
tion factors elicit a positive response to oxidative stress
but FOXO, binding with β-catenin, may induce apoptosis
whereas PPARγ increases the expression of the antiapoptotic
Bcl-2. The relation PPARγ-FOXO is ambivalent: FOXO
directly inhibits PPARγ and indirectly induces it, sinking the
negative effect of Wnt/β-catenin; on the other hand PPARγ
acting exclusively indirectly is both inducer and repressor.
This complicated relationship probably reflects the different
effect on apoptosis, clearly proapoptotic FOXO, mostly an-
tiapoptotic PPARγ. PPARγ may retard apoptosis inducing
Bcl-2 and inhibiting FOXO; however this mechanism is
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Table 2: Main experimental data linking PPARγ to NRF2, Wnt/β-catenin, and FOXO pathways.
Interaction Gene Target Effect Tissue or cell type
Type of
evidence
References
NRF2-
PPARγ
NRF2 PPARγ ↑ expression Liver, lung In vitro
In vivo
[79–81]
PPARγ NRF2 ↑ expression Lung, hepatocytes, macrophages, vascular tissue In vitro
In vivo
[73, 77, 80,
82]
Wnt/β-
catenin-
PPARγ
Wnt/β-
catenin
PPARγ ↓expression Pre-adipocytes, adipocytes, skeleton, hepatic stellate cells,
neurons, cancer cells
In vitro
In vivo
[6, 90,
117–121]
PPARγ
Wnt/β-
catenin
↓transcriptional
activity
↑ proteasomal
degradation
↑ cytoplasmic
localization
Colon, small intestine, colon cancer cells, hepatocytes,
myeloid and lymphoid leukemic cells
In vitro
In vivo
[122–128]
FOXO-
PPARγ
FOXO PPARγ
↓ expression
↓ activity Adipocytes
In vitro
In vivo
[129–132]
PPARγ FOXO ↓ activity Adipocytes In vitro [129]
↑ = increasing; ↓ = decreasing.
self-limiting because activating FOXO, PPARγ creates a
negative loop that may increase the chances of cellular death.
Interestingly PPARγ may be the bridge linking NRF2
to Wnt/β-catenin and FOXO pathways. Activating PPARγ,
NRF2 not only potentiate the cellular oxidative response
but may also overcome the negative feedback loop PPARγ-
Wnt/β-catenin inducing cell cycle arrest giving more time
to the cells to repair the damage; at the same time,
through PPARγ, NRF2 may fine-tune the stress resistance
and apoptotic FOXO-mediated responses to oxidative stress.
However, because of the multiple regulatory links we have
described, this interaction goes in both ways giving that
Wnt/β-catenin and FOXO, inhibiting PPARγ, may influence
NRF2 activity.
Although the experimental pieces of evidence recollected
in this paper have been obtained from various experimental
models and conditions (see Tables 1 and 2) and need further
verifications, they clearly suggest that the role of PPARγ
in oxidative stress is essentially devoted to the quenching
and containment of the damage and to foster cell survival;
furthermore they depict a new signaling network NRF2-
PPARγ-Wnt/β-catenin-FOXO that may be exploited for the
treatment of oxidative-related diseases.
In conclusion, during oxidative stress PPARγ promotes
an antioxidant response integrating NRF2, Wnt/β-catenin,
and FOXO pathways, but clearly the end result of oxidative
stress, survival or apoptotic death, does not depend only
on these sole genes but also on the net effect of other
signaling pathways and regulatory circuits that converge on,
and interact with, these transcription factors.
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